Stoke Therapeutics grants options for 245,920 shares to 18 new employees
STOK•Stoke Therapeutics granted options for 245,920 common shares to 18 new employees, including 70,000 shares to Senior Vice President and Chief Information Officer Stephen Aschettino. The options have a $24.61 exercise price, a 10-year term and four-year vesting schedules, subject to continued employment.
1. Option grant details
The grants took effect October 15, 2026, under Stoke Therapeutics’ 2023 Inducement Plan. Twenty-five percent of each award vests on the first anniversary of its applicable vesting commencement date; the remaining shares vest monthly at 1/48 of each award over 36 months, subject to continued employment.
